Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude sur le TP-3654 oral chez des patients atteints de myélofibrose

30 septembre 2026 mis à jour par: Sumitomo Pharma America, Inc.

Une étude de phase 1/2, ouverte, à dose croissante, d'innocuité, pharmacocinétique et pharmacodynamique du TP-3654 par voie orale chez des patients atteints de myélofibrose primaire ou secondaire à risque intermédiaire ou élevé

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Aperçu de l'étude

Description détaillée

Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.

Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.

Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)

Type d'étude

Interventionnel

Inscription (Estimé)

240

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Halle, Allemagne
        • Recrutement
        • Universitätsmedizin Halle
        • Contact:
          • SMPA Investigative Site
      • Lübeck, Allemagne
        • Recrutement
        • Universitätsklinikum Schleswig-Holstein
        • Contact:
          • SMPA Investigative Site
      • Adelaide, Australie
        • Recrutement
        • Icon Cancer Centre (Ashford Cancer Centre Research)
        • Contact:
    • South Australia
      • Adelaide, South Australia, Australie
    • Victoria
      • Box Hill, Victoria, Australie
        • Recrutement
        • Eastern Health Box Hill Hospital
        • Contact:
          • SMPA Investigative Site
      • Clayton, Victoria, Australie
        • Recrutement
        • Monash University
        • Contact:
          • SMPA Investigative Site
      • Fitzroy, Victoria, Australie
        • Recrutement
        • St Vincent's Hospital Melbourne
        • Contact:
          • SMPA Investigative Site
      • Melbourne, Victoria, Australie
        • Recrutement
        • Peter McCallum Center
        • Contact:
          • SMPA Investigative Site
      • Richmond, Victoria, Australie
        • Recrutement
        • Epworth Healthcare
        • Contact:
          • SMPA Investigative Site
      • Antwerp, Belgique, 2020
        • Recrutement
        • ZNA Cadix
        • Contact:
          • SMPA Investigative Site
      • Antwerp, Belgique, 2030
        • Recrutement
        • ZNA Middelheim
        • Contact:
          • SMPA Investigative Site
      • Ghent, Belgique, 9000
        • Recrutement
        • Universitair Ziekenhuis Gent
        • Contact:
          • SMPA Investigative Site
      • Liège, Belgique, 4000
        • Recrutement
        • CHU de Liege
        • Contact:
          • SMPA Investigative Site
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgique, 3000
        • Recrutement
        • University Hospitals Leuven
        • Contact:
          • SMPA Investigative Site
    • Alberta
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Recrutement
        • University of British Columbia
        • Contact:
          • SMPA Investigative Site
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Recrutement
        • St. Paul's Hospital Hematology/Oncology Research
        • Contact:
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Recrutement
        • Juravinski Cancer Center
        • Contact:
          • SMPA Investigative Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Recrutement
        • Princess Margaret Cancer Center
        • Contact:
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Recrutement
        • Jewish General Hospital
        • Contact:
          • SMPA Investigative Site
      • Barcelona, Espagne
        • Recrutement
        • Hospital Universitario y Politecnico La Fe
        • Contact:
          • SMPA Investigative Site
      • Barcelona, Espagne
        • Recrutement
        • Institut Catala d'Oncologia
        • Contact:
          • SMPA Investigative Site
      • Salamanca, Espagne
        • Recrutement
        • Hospital Universitario de Salamanca
        • Contact:
          • SMPA Investigative Site
      • Amiens, France, 80054
        • Recrutement
        • Centre Hospitalier Universitaire D'Amiens
        • Contact:
          • SMPA Investigative Site
      • Angers, France, 9000
        • Recrutement
        • CHU Angers
        • Contact:
          • SMPA Investigative Site
      • Lyon, France, 69495
        • Recrutement
        • Centre Hospitalier Lyon Sud
        • Contact:
          • SMPA Investigative Site
      • Nice, France, 06200
        • Recrutement
        • Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
        • Contact:
          • SMPA Investigative Site
      • Nîmes, France, 30029
        • Recrutement
        • Institut de cancerologie du Gard
        • Contact:
          • SMPA Investigative Site
      • Nîmes, France
        • Recrutement
        • Institut de cancerologie du Gard
        • Contact:
          • SMPA Investigative Site
      • Paris, France, 75010
        • Recrutement
        • Hospital Saint Louis
        • Contact:
          • SMPA Investigative Site
      • Poitiers, France, 86021
        • Recrutement
        • University Hospital of Poitiers
        • Contact:
          • SMPA Investigative Site
      • Villejuif, France, 94805
        • Recrutement
        • Institut Gustave Roussy
        • Contact:
          • SMPA Investigative Site
      • Alessandria, Italie, 15121
        • Recrutement
        • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
        • Contact:
          • SMPA Investigative Site
      • Aviano, Italie, 33081
        • Recrutement
        • Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
      • Bologna, Italie, 40138
        • Recrutement
        • IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
        • Contact:
          • SMPA Investigative Site
      • Brescia, Italie
        • Recrutement
        • ASST - Spedali Civili di Brescia
        • Contact:
          • SMPA Investigative Site
      • Meldola, Italie, 47014
        • Recrutement
        • IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
        • Contact:
          • SMPA Investigative Site
      • Milan, Italie, 20122
        • Recrutement
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Contact:
          • SMPA Investigative Site
      • Torino, Italie, 10126
        • Recrutement
        • Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
        • Contact:
          • SMPA Investigative Site
      • Aichi, Japon
      • Aomori, Japon
        • Recrutement
        • Aomori Prefectural Central Hospital
        • Contact:
      • Chiba, Japon
        • Recrutement
        • National Cancer Center Hospital East
        • Contact:
      • Fukuoka, Japon
      • Hokkaido, Japon
        • Recrutement
        • Hokkaido University Hospital
        • Contact:
      • Kamakura, Japon, 247-8533
        • Recrutement
        • Shonan Kamakura General Hospital
        • Contact:
      • Miyazaki, Japon
        • Recrutement
        • University of Miyazaki Hospital
        • Contact:
      • Okayama, Japon
        • Recrutement
        • Okayama University Hospital
        • Contact:
      • Osaka, Japon
        • Recrutement
        • The University of Osaka Hospital
        • Contact:
          • Michiko Ichii, MD
          • Numéro de téléphone: 06-6879-5111
      • Saitama, Japon
        • Complété
        • Saitama Medical Center
      • Sendai, Japon
        • Recrutement
        • Tohoku University Hospital
        • Contact:
          • Noriko Fukuhara, MD
          • Numéro de téléphone: 022-717-7000
      • Shizuoka, Japon
        • Complété
        • Shizuoka Cancer Center
      • Tokyo, Japon, 160-0023
        • Recrutement
        • Tokyo Medical University Hospital
        • Contact:
      • Tokyo, Japon
        • Recrutement
        • Juntendo University Hospital
        • Contact:
      • Tokyo, Japon, 179-0072
        • Recrutement
        • Nerima Hikarigaoka Hospital
        • Contact:
      • Tsu, Japon
      • Lincoln, Royaume-Uni
        • Recrutement
        • Lincoln County Hospital
        • Contact:
          • SMPA Investigative Site
      • Lincoln, Royaume-Uni
        • Recrutement
        • United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
        • Contact:
          • SMPA Investigative Site
      • London, Royaume-Uni
        • Recrutement
        • University College London Hospital's NHS foundation Trust
        • Contact:
          • SMPA Investigative Site
      • Oxford, Royaume-Uni
        • Recrutement
        • Oxford University Hospitals NHS Foundation
        • Contact:
          • SMPA Investigative Site
    • Alabama
      • Birmingham, Alabama, États-Unis, 35294
        • Recrutement
        • University of Alabama
        • Contact:
          • Tiffany Hill
          • Numéro de téléphone: 205-934-9591
    • Arizona
      • Tucson, Arizona, États-Unis, 85724
        • Recrutement
        • The University of Arizona Cancer Center
        • Contact:
    • California
      • Duarte, California, États-Unis, 91010
        • Recrutement
        • City of Hope
        • Contact:
      • Los Angeles, California, États-Unis, 90033
        • Recrutement
        • University of Southern California
        • Contact:
      • Newport Beach, California, États-Unis, 92663
        • Recrutement
        • Hoag Family Cancer Institute
        • Contact:
    • Colorado
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06510
        • Recrutement
        • Yale School of Medicine
        • Contact:
    • Florida
      • Gainesville, Florida, États-Unis, 32608
        • Complété
        • University of Florida Health Shands Cancer Hospital
      • Miami, Florida, États-Unis, 33136
        • Recrutement
        • University of Miami
        • Contact:
          • Alessia Zoso
          • Numéro de téléphone: 305-243-0327
          • E-mail: azoso@miami.edu
      • Miami, Florida, États-Unis, 33176
        • Recrutement
        • Baptist Health - Miami Cancer Institute
        • Contact:
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
    • Illinois
      • Chicago, Illinois, États-Unis, 60637
    • Maryland
      • Baltimore, Maryland, États-Unis, 21201
        • Recrutement
        • University of Maryland
        • Contact:
          • Maria Baer, MD
          • Numéro de téléphone: 410-328-8708
          • E-mail: mbaer@umm.edu
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
        • Recrutement
        • Massachusetts General Hospital
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • Recrutement
        • University of Michigan
        • Contact:
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55455
        • Recrutement
        • University of Minnesota
        • Contact:
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University of Medicine
        • Contact:
    • New Jersey
      • Hackensack, New Jersey, États-Unis, 07601
        • Recrutement
        • John Theurer Cancer Center at Hackensack University Medical Center
        • Contact:
    • New York
      • Buffalo, New York, États-Unis, 14263
        • Complété
        • Roswell Park Comprehensive Cancer Center
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Memorial Sloan Kettering Cancer Center
        • Contact:
      • New York, New York, États-Unis, 10029
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Weill Cornell Medical Center
        • Contact:
      • The Bronx, New York, États-Unis, 10461
    • North Carolina
      • Durham, North Carolina, États-Unis, 27710
    • Ohio
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • Ohio State University
        • Contact:
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • Recrutement
        • Medical University of South Carolina
        • Contact:
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Recrutement
        • Vanderbilt University
        • Contact:
          • SMPA Investigative Site
      • Nashville, Tennessee, États-Unis, 37203
    • Texas
      • Houston, Texas, États-Unis, 77054
        • Recrutement
        • MD Anderson Cancer Center
        • Contact:
    • Utah
      • Salt Lake City, Utah, États-Unis, 84112
        • Recrutement
        • Huntsman Cancer Institute
        • Contact:
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22903
        • Recrutement
        • University of Virginia Cancer Center
        • Contact:
    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Recrutement
        • University of Washington - Fred Hutchinson Cancer Center
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Patients must meet all of the following inclusion criteria to be eligible:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
  • Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
  • Fulfill the following clinical laboratory parameters:
  • Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
  • ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5%
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
  • Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
  • Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
  • On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
  • Fulfills the following clinical laboratory parameters:
  • Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Nuvisertib (TP-3654) + Momelotinib Arm

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
  • Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
  • Fulfills the following clinical laboratory parameters:
  • Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
  • Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy.
  • Prior allogeneic stem cell transplant within the last 6 months.
  • Eligible for allogeneic bone marrow or stem cell transplantation.
  • Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
  • History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
  • Corrected QT interval > 480msec.
  • Prior or concurrent malignancy that could interfere with the investigational regime.
  • Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
  • Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
  • Pregnant or breastfeeding
  • Currently receiving any other investigational agent.

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
  • Known allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy
  • Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Nuvisertib (TP-3654) + Momelotinib Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
  • Splenic irradiation within 6 months prior to screening or prior splenectomy
  • Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • Presence of Grade ≥ 2 peripheral neuropathy
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Bras 1 : nuvisertib (TP-3654)

Oral PIM Inhibitor

Autres noms:
  • TP-3654
Expérimental: Bras 2 : nuvisertib (TP-3654) ajouté au ruxolitinib

Oral PIM Inhibitor

Autres noms:
  • TP-3654

Oral JAK inhibitor

Autres noms:
  • Jakafi
Expérimental: Bras 3 : nuvisertib (TP-3654) en association avec le momelotinib

Oral PIM Inhibitor

Autres noms:
  • TP-3654

Oral JAK inhibitor

Autres noms:
  • Ojjaara

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Determine the incidence of dose-limiting toxicities (DLTs)
Délai: 28 days

Number of participants with DLTs

28 days
Determine the incidence of treatment emergent adverse events
Délai: From start of treatment to end of study

Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events

From start of treatment to end of study
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Délai: From start of treatment to end of study

Number of participants with ≥ 35% spleen volume reduction (SVR35)

From start of treatment to end of study

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of participants achieving objective response by IWG-MRT response criteria
Délai: From start of treatment to end of study

Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease.

From start of treatment to end of study
Number of participants who have ≥ 25% spleen volume reduction
Délai: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.

Number of participants who have ≥ 25% spleen volume reduction compared to baseline

Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Délai: 24 weeks

Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment.

24 weeks
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Délai: After 24 weeks of treatment to end of study

Change in PGIC score

After 24 weeks of treatment to end of study
Determine the incidence of QT interval changes
Délai: 25 hours

Changes in QT interval and heart rhythm

25 hours
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Délai: 24 hours

The estimate of time for the nuvisertib concentration or amount to be reduced by half

24 hours
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Délai: 24 hours

The amount of drug exposure over 24 hours period after administration

24 hours
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Délai: 24 hours

The maximum nuvisertib concentration after administration

24 hours
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Délai: 24 hours

The time to reach maximum nuvisertib concentration

24 hours

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Nombre de patients présentant une réduction de la fibrose médullaire
Délai: Toutes les 24 semaines jusqu'à la fin des études
Toutes les 24 semaines jusqu'à la fin des études
Bras combinés Nuvisertib : évaluer l'augmentation du taux d'hémoglobine ≥ 1,5 ou ≥ 2 g/dL par rapport à la valeur initiale.
Délai: Du début du traitement à la fin des études
Du début du traitement à la fin des études
Bras combinés Nuvisertib : évaluer le statut d'indépendance transfusionnelle de globules rouges ou tout changement d'exigence
Délai: Du début du traitement à la fin des études
Du début du traitement à la fin des études
Nuvisertib Monotherapy: Changements du nombre de plaquettes au fil du temps chez les patients présentant un nombre de plaquettes de base <100 x 10 ^ 9 / L
Délai: Du début du traitement à la fin de l'étude
Du début du traitement à la fin de l'étude
Study potential pharmacodynamic (PD) markers of nuvisertib
Délai: 12 months

Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples.

12 months
Establish overall survival
Délai: From start of treatment to end of study

The time interval from treatment start date to date of death from any cause

From start of treatment to end of study

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 décembre 2019

Achèvement primaire (Estimé)

30 avril 2027

Achèvement de l'étude (Estimé)

30 avril 2030

Dates d'inscription aux études

Première soumission

8 novembre 2019

Première soumission répondant aux critères de contrôle qualité

22 novembre 2019

Première publication (Réel)

25 novembre 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner